DeepPsy AG

At DeepPsy, we empower psychiatrists to make data-driven treatment decisions for patients with depression by analyzing electrophysiological signals, specifically EEG and ECG. Our proprietary biomarkers offer predictive insights into treatment response, helping clinicians select the most effective intervention when multiple options appear clinically viable. We are actively deploying this technology in clinics across Switzerland, where it is being used to personalize rTMS (repetitive Transcranial Magnetic Stimulation) protocols based on EEG-derived markers. Our validated biomarkers not only differentiate between SSRI and SNRI responses, but also predict outcomes for innovative treatments such as ketamine. Our software is already registered in Switzerland and the UK, and the treatment is reimbursed by health insurance in Switzerland, making a strong testament to the clinical and regulatory validation of our work. Beyond individual care, we support pharmaceutical companies by enabling precision stratification of patient populations in clinical trials. This enhances both the efficiency and the success rates of psychiatric drug development pipelines. With regulatory traction, clinical validation, and active deployment in Swiss clinics, DeepPsy is transitioning from early-stage innovation to scalable implementation. As the global need for personalized mental health care grows, so does the opportunity for investors to join us in transforming psychiatric treatment. Investing in DeepPsy means backing a company that: • Has clinically validated, reimbursed, and registered products. • Uses cutting-edge AI to tackle a pressing global health issue. • Has a scalable platform with applications in both clinical and pharmaceutical contexts. • Is positioned to become a leader in precision psychiatry. We believe that everyone receiving psychiatric medication deserves a personalized, evidence-based treatment.